Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EBS NASDAQ:GERN NASDAQ:MYGN NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEBSEmergent Biosolutions$9.65+2.4%$8.76$4.02▼$12.73$503.10M2.04884,954 shs623,281 shsGERNGeron$1.22-1.6%$1.34$1.09▼$4.50$791.14M0.577.42 million shs3.30 million shsMYGNMyriad Genetics$8.05+2.4%$7.16$3.76▼$22.92$731.33M1.971.03 million shs759,969 shsNVAXNovavax$8.36-1.2%$8.42$5.01▼$11.55$1.37B2.744.77 million shs3.00 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEBSEmergent Biosolutions-0.07%-1.78%+15.92%+26.44%+2.42%GERNGeron-2.36%-3.13%-6.77%-3.13%-69.08%MYGNMyriad Genetics-2.48%-2.96%+0.26%+69.03%-65.25%NVAXNovavax-1.51%-5.05%-4.62%+10.73%-16.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEBSEmergent Biosolutions$9.65+2.4%$8.76$4.02▼$12.73$503.10M2.04884,954 shs623,281 shsGERNGeron$1.22-1.6%$1.34$1.09▼$4.50$791.14M0.577.42 million shs3.30 million shsMYGNMyriad Genetics$8.05+2.4%$7.16$3.76▼$22.92$731.33M1.971.03 million shs759,969 shsNVAXNovavax$8.36-1.2%$8.42$5.01▼$11.55$1.37B2.744.77 million shs3.00 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEBSEmergent Biosolutions-0.07%-1.78%+15.92%+26.44%+2.42%GERNGeron-2.36%-3.13%-6.77%-3.13%-69.08%MYGNMyriad Genetics-2.48%-2.96%+0.26%+69.03%-65.25%NVAXNovavax-1.51%-5.05%-4.62%+10.73%-16.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEBSEmergent Biosolutions 2.33Hold$13.5039.85% UpsideGERNGeron 2.13Hold$3.79210.30% UpsideMYGNMyriad Genetics 2.13Hold$12.4554.71% UpsideNVAXNovavax 1.88Reduce$10.0019.62% UpsideCurrent Analyst Ratings BreakdownLatest EBS, NVAX, GERN, and MYGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/23/2025NVAXNovavaxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.0010/14/2025MYGNMyriad GeneticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025EBSEmergent BiosolutionsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025GERNGeronWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NVAXNovavaxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025EBSEmergent BiosolutionsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025GERNGeronWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MYGNMyriad GeneticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NVAXNovavaxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/3/2025EBSEmergent BiosolutionsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/28/2025NVAXNovavaxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEBSEmergent Biosolutions$1.04B0.49$1.97 per share4.91$8.91 per share1.08GERNGeron$76.99M10.11N/AN/A$0.46 per share2.65MYGNMyriad Genetics$837.60M0.89$1.02 per share7.87$7.70 per share1.05NVAXNovavax$682.16M1.99N/AN/A($3.89) per share-2.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEBSEmergent Biosolutions-$190.60M$2.453.944.66N/A16.38%24.63%8.97%10/29/2025 (Estimated)GERNGeron-$174.57M-$0.13N/AN/AN/A-53.52%-31.37%-16.01%11/6/2025 (Estimated)MYGNMyriad Genetics-$127.30M-$4.28N/AN/AN/A-47.45%-5.17%-3.44%11/6/2025 (Estimated)NVAXNovavax-$187.50M$2.283.67104.500.1139.20%-142.33%28.65%11/11/2025 (Estimated)Latest EBS, NVAX, GERN, and MYGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025NVAXNovavax-$0.44N/AN/AN/A$55.63 millionN/A11/6/2025Q3 2025GERNGeron-$0.03N/AN/AN/A$55.24 millionN/A11/6/2025Q3 2025MYGNMyriad Genetics-$0.01N/AN/AN/A$205.26 millionN/A10/29/2025Q3 2025EBSEmergent Biosolutions-$0.01N/AN/AN/A$203.67 millionN/A8/6/2025Q2 2025EBSEmergent Biosolutions-$0.26$0.16+$0.42-$0.22$148.55 million$140.90 million8/6/2025Q2 2025GERNGeron-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 million8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEBSEmergent BiosolutionsN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEBSEmergent Biosolutions1.255.663.00GERNGeron0.467.876.79MYGNMyriad GeneticsN/A1.421.28NVAXNovavax5.932.362.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEBSEmergent Biosolutions78.40%GERNGeron73.71%MYGNMyriad Genetics99.02%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipEBSEmergent Biosolutions1.20%GERNGeron7.42%MYGNMyriad Genetics2.40%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEBSEmergent Biosolutions2,42053.35 million52.71 millionOptionableGERNGeron70638.02 million590.68 millionOptionableMYGNMyriad Genetics2,70093.04 million90.81 millionOptionableNVAXNovavax1,990162.42 million160.80 millionOptionableEBS, NVAX, GERN, and MYGN HeadlinesRecent News About These CompaniesNovavax to assign Gaithersburg, Md. facility to AstraZeneca for $60BOctober 23 at 4:15 PM | msn.comNovavax: Sell Rating Due to Declining Vaccine Demand and Financial ChallengesOctober 23 at 5:51 AM | tipranks.comNovavax signs $60 million agreements to trim US portfolioOctober 22 at 7:31 PM | reuters.comNovavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to NoteOctober 22 at 6:45 PM | zacks.comNovavax Enters Lease Agreement with AstraZenecaOctober 22 at 9:51 AM | tipranks.comNovavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate StrategyOctober 22 at 7:00 AM | prnewswire.comNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItOctober 21 at 10:00 AM | zacks.comNovavax, Inc. (NASDAQ:NVAX) Receives Average Recommendation of "Reduce" from AnalystsOctober 20 at 2:23 AM | americanbankingnews.comNovavax, Inc. (NASDAQ:NVAX) Given Consensus Recommendation of "Reduce" by BrokeragesOctober 20 at 2:22 AM | marketbeat.comNovavax (NVAX) Suffers a Larger Drop Than the General Market: Key InsightsOctober 16, 2025 | zacks.comNovavax, Inc. $NVAX Shares Acquired by Bayforest Capital LtdOctober 15, 2025 | marketbeat.comNovavax stock rises after major shareholder urges company saleOctober 14, 2025 | za.investing.comShah Capital pushes for Novavax’s sale on underperformance, Reuters saysOctober 14, 2025 | msn.comNovavax Major Shareholder Calls For Sale Of Company To Larger Pharma EntityOctober 14, 2025 | msn.comHedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion PotentialOctober 14, 2025 | benzinga.comAnalysts Think These Stocks Could More Than Double in Value (NVAX)...October 14, 2025 | marketbeat.comShah Capital pushes for Novavax's sale on persistent underperformance, marketing misstepsOctober 14, 2025 | reuters.comNovavax (NASDAQ:NVAX) Receives Sell (D+) Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comInvestors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to KnowOctober 8, 2025 | zacks.comNovavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone PaymentOctober 7, 2025 | prnewswire.comShah Capital Management Has $72.52 Million Stock Position in Novavax, Inc. $NVAXOctober 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 20253 Small-Cap Stocks to Watch After the Fed’s Rate CutsBy Chris Markoch | September 24, 2025EBS, NVAX, GERN, and MYGN Company DescriptionsEmergent Biosolutions NYSE:EBS$9.65 +0.22 (+2.36%) Closing price 03:59 PM EasternExtended Trading$9.65 +0.00 (+0.02%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Geron NASDAQ:GERN$1.22 -0.02 (-1.61%) Closing price 04:00 PM EasternExtended Trading$1.24 +0.02 (+1.23%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Myriad Genetics NASDAQ:MYGN$8.05 +0.19 (+2.42%) Closing price 04:00 PM EasternExtended Trading$8.15 +0.10 (+1.29%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Novavax NASDAQ:NVAX$8.36 -0.10 (-1.18%) Closing price 04:00 PM EasternExtended Trading$8.38 +0.03 (+0.30%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
